OncLive TV

A. Oliver Sartor, MD, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer.

Yelena Y. Janjigian, MD, discusses the rationale behind the plasma and tumor-based biomarker analysis of pembrolizumab in combination with trastuzumab and chemotherapy in HER2-positive metastatic esophagogastric cancer.

Chung-Han Lee, MD, PhD, discusses the efficacy of combining immunotherapy with TKIs to treat patients with metastatic renal cell carcinoma.

Naval G. Daver, MD, discusses the mechanism of action of the investigational CD47-directed antibody magrolimab in acute myeloid leukemia and myelodysplastic syndrome.

A. Oliver Sartor, MD, discusses the rationale for investigating the sequential use of beta emitters and alpha emitters in metastatic castration-resistant prostate cancer.

Andrei Gafita, MD, discusses sequencing lutetium-177 PSMA-617 in metastatic castration-resistant prostate cancer.

Jorge E. Cortes, MD, discusses the benefits of ruxolitinib (Jakafi) in patients with myeloproliferative neoplasms.

Sagar Lonial, MD, FACP, discusses some of the remaining challenges to address in the multiple myeloma space.

Kim Chi, MD, senior research scientist, Vancouver Prostate Centre, discusses clinical challenges in prostate cancer.

Brian M. Slomovitz, MD, discusses sequencing strategies for endometrial cancer.

Shilpa Gupta, MD, discusses the potential utility of neoadjuvant versus adjuvant immunotherapy in urothelial carcinoma.

Andrew Coveler, MD, discusses the investigational CD40-directed monoclonal antibody SEA-CD40 in combination with gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Isabella C. Glitza Oliva, MD, PhD, MS, discusses the rationale for concurrent intrathecal and intravenous nivolumab in patients with metastatic melanoma who have leptomeningeal disease.

Andrew Branagan, MD, discusses novel induction therapies being used with transplant to improve outcomes in patients with multiple myeloma.

Richard R. Furman, MD, discusses the safety of acalabrutinib as a monotherapy in hematologic malignancies.

Reem Karmali, MD, MS, discusses an analysis examining clinical outcomes and predictors of survival in older patients with mantle cell lymphoma in the era of rituximab.

Robert L. Coleman, MD, FACOG, FACS, discusses the utility of biomarkers in precision medicine.

William R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.

Parameswaran Hari, MD, MRCP, discusses the current and potential future utility of ixazomib (Ninlaro) maintenance in multiple myeloma.

Shaji K. Kumar, MD, discusses key takeaways from the phase 3 ENDURANCE trial in newly diagnosed multiple myeloma.

Hun Ju Lee, MD, discusses novel targets in lymphomas and leukemias.

Jesus G. Berdeja, MD, discusses updated safety results from the ongoing phase 1b/2 CARTITUDE-1 trial (NCT03548207) with the CAR T-cell therapy JNJ-4528 in multiple myeloma.

Michael J. Morris, MD, discusses the promising future of prostate-specific membrane antigen–targeted PET imaging in prostate cancer.

Preetesh Jain, MD, PhD, discusses the activity of venetoclax (Venclexta) in mantle cell lymphoma (MCL).

Mark M. Awad, MD, PhD, discusses acquired resistance to MET inhibitors in MET exon 14 skipping (METex14)–mutated non–small cell lung cancer (NSCLC).

Jia Ruan, MD, PhD, discusses the impact of BTK inhibitors in mantle cell lymphoma (MCL).

Jeff P. Sharman, MD, discusses unmet clinical needs in the treatment of patients with high-risk relapsed/refractory chronic lymphocytic leukemia.

Denise Yardley, MD, discusses treatment considerations for patients with advanced breast cancer who have visceral metastases.

Brian M. Slomovitz, MD, discusses the importance of developing sequencing strategies in endometrial cancer treatment.

David Polsky, MD, PhD, on the association between circulating tumor DNA and survival in melanoma.